Formycon AG (FYB.DE) stock: Winston Score, insiders and Congress trades

Formycon AG is a German biotechnology company that develops biosimilars — copycat versions of expensive biological medicines that have lost patent protection. Its main focus is on eye diseases, inflammatory conditions, and other serious illnesses. The company's pipeline includes biosimilar versions of well-known drugs like Eylea and Stelara, targeting hospitals, clinics, and healthcare systems looking for lower-cost treatment options. Formycon earns money primarily through licensing deals and partnerships with larger pharmaceutical companies, which pay Formycon to develop and commercialize biosimilars on their behalf. The company is based in Munich, Germany, and operates mainly in European and North American markets. Its competitive position relies on deep technical expertise in developing complex biological molecules, but with an operating margin of -66% and a small market cap of roughly $0.4 billion, the key risk is whether licensing revenue and future product approvals can outpace ongoing research and development costs before the company needs additional funding.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-05.